Navigation Links
Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment
Date:6/17/2008

- 64% of expectant or new mothers say that diaper rash is only a minor

problem - 57% are unaware that diaper rash can be accompanied by a doctor diagnosed

yeast infection called Candida, affecting both girls and boys - 59% responded "no" or were unsure when asked if there was a connection

between diaper rash and antibiotics

PRINCETON, N.J., June 17 /PRNewswire-FirstCall/ -- Barrier Therapeutics, Inc. (Nasdaq: BTRX), a pharmaceutical company that develops and markets dermatology products, today published its first annual Vusion Baby Bottom Line Report that includes results from a nationwide survey of new and expectant mothers. Conducted by Penn, Schoen & Berland Associates, the report found that new and expectant mothers do not know that some diaper rash can be so severe that it may require prescription drug treatment. More importantly, many moms (52 percent) are unsure or do not know when to see a healthcare provider about their babies' severe diaper rash.

"Many of the cases of persistent diaper rash that I treat involve a yeast infection," said Dr. Jennifer Shu, a pediatrician in Atlanta, GA, and co-author of Heading Home with Your Newborn: From Birth to Reality. "However, parents don't always know that yeast is a common cause of these rashes, which can get worse without proper treatment."

According to the survey:

-- Fewer than one in five moms could identify any of the defined

differences between normal diaper rash and more serious or severe

diaper rash

-- Only 29% of moms know that a severe diaper rash with yeast infection

can progress quickly

-- Only one in five (20%) of moms are aware that over-the-counter

medications are not approved to treat this condition

-- Nearly half of moms (43%) incorrectly believe or are not sure that

cloth diapers prevent diaper rash

Candida, a specific type of yeast, is commonly found in the intestinal tract and is carried to the diaper area by a baby's stool. A microscopic evaluation is needed to determine if a baby is suffering from Diaper Dermatitis complicated by documented Candidiasis (DDCC). Treating DDCC, along with a regimen of cleansing and frequent diaper changes, may require the use of a prescription skin medication.

Antibiotics are a common cause of diaper rash with yeast infection as they affect the bacterial flora in the intestinal tract, thus allowing Candida (yeast infection) an increased opportunity to multiply. Candida can worsen a diaper rash, leaving a baby uncomfortable.

While almost every baby experiences one or more episodes of diaper rash before he is toilet-trained, a healthcare provider can confirm if a child's rash is accompanied by an infection. It is important that moms consult their physician if their child's rash lasts 2-3 days or the skin in the area presents with pustules (red spots) or with a beefy red appearance.

"Barrier Therapeutics is committed to increasing the awareness of parents about skin conditions, including diaper rash with documented yeast infection," said Dr. Braham Shroot, Ph.D., Chief Scientific Officer, Barrier Therapeutics Inc. "This is important because we have discovered that parents are quite unfamiliar with this condition and we encourage them to seek advice from their health care provider."

About Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment

In 2006, Vusion Ointment was approved by the U.S. Food and Drug Administration (FDA) to safely and effectively treat diaper rash with a documented yeast infection. Vusion ointment is the first and only product approved by the FDA to treat this condition and can be prescribed to infants as young as four weeks with a normal immune system.

"Vusion Ointment is the only medication specifically approved by the FDA to treat diaper rash complicated by yeast," said Dr. Shu. "The fact that Vusion Ointment has three active ingredients in one tube makes it more practical when you're trying to treat a yeast infection while also helping protect and heal the skin. Unlike other forms of treatment, this combination allows parents and other caregivers to apply a single ointment at every diaper change for up to seven days."

For more information

To learn more about the signs of severe diaper rash and Vusion Ointment or for full prescribing information, please visit http://www.vusionointment.com or http://www.barriertherapeutics.com.

Important Information about Vusion Ointment

Vusion Ointment is a prescription skin medicine used to treat diaper rash with a documented yeast infection in children 4 weeks and older who have a normal immune system. Your healthcare provider will need to confirm that your child's diaper rash is also complicated by a yeast infection. Do not use Vusion Ointment on your child's diaper rash unless your healthcare provider tells you that there is also a yeast infection present.

Vusion Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper rash, including gentle cleansing of the diaper area and frequent diaper changes. Vusion Ointment contains medicines that will help treat the yeast infection and the diaper rash, but you must also change your child's diapers often so that your child is not wearing a wet or soiled diaper. Even if you use Vusion Ointment, diaper rash will not go away if you do not keep your child's diaper area clean and dry. Vusion Ointment should not be used to prevent diaper rash nor used for longer than 7 days because preventative use may not allow the treatment to work as well over time. If irritation occurs, or if the rash worsens, stop treatment and contact your healthcare provider.

About Barrier Therapeutics

Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: http://www.barriertherapeutics.com.

Xolegel, Vusion and Solage are registered trademarks of Barrier Therapeutics, Inc.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Contact: Barrier Therapeutics, Inc. 1-866-440-5508,

Kelly Sutt, 609-945-1235, ksutt@barriertherapeutics.com

Ruder Finn, Christoph Miller, 212-593-6495,

millerc@ruderfinn.com


'/>"/>
SOURCE Barrier Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Philadelphia Washed-Up ... Region Near Bottom
2. Bottomless bowls are an Ig Nobel winner
3. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
4. Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
5. Free White Paper From The Beryl Institute Quantifies Bottom-Line Impact of Corporate Culture
6. Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line
7. Report: Life And Death Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S.
8. Mental Health & Addiction Among Working Parents & Children Affects the Bottom Line: Research Shows Staggering Economic Impact
9. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
10. New Report: Dangerous Drug Side Effects and Deaths Doubled Since 1998... Seniors Hit Hardest
11. New Report: Increasing Oregons Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: